TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma

被引：0
|
作者：
Reiter, Florian P. [1 ]
Geier, Andreas [1 ]
机构：
[1] Univ Hosp Wurzburg, Dept Med 2, Div Hepatol, D-97080 Wurzburg, Germany
来源：
LANCET | 2025年 / 405卷 / 10474期
关键词：
LOCOREGIONAL THERAPIES; END-POINTS; SURVIVAL;
D O I：
10.1016/S0140-6736(24)02680-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：174 / 176
页数：3
相关论文
共 50 条
  • [31] Theoretic strategy for immune checkpoint inhibitor-based combination therapy
    Chamoto, Kenji
    Hung, Mien-Chie
    CANCER SCIENCE, 2022, 113 : 1247 - 1247
  • [32] Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis
    Wang, Junpeng
    Li, Xin
    Wu, Xiaoqiang
    Wang, Zhiwei
    Zhang, Chan
    Cao, Guanghui
    Zhang, Xiaofan
    Peng, Feng
    Yan, Tianzhong
    EBIOMEDICINE, 2019, 47 : 78 - 88
  • [33] Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy
    He, Mengying
    Yang, Tao
    Wang, Yuhan
    Wang, Mengyuan
    Chen, Xingye
    Ding, Dawei
    Zheng, Yiran
    Chen, Huabing
    ADVANCED HEALTHCARE MATERIALS, 2021, 10 (09)
  • [34] Immune Checkpoint Inhibitor-Based Systemic Therapy Shows Remarkable Curative Effect in a Hepatocellular Carcinoma Patient With Intractable Postoperative Recurrence and Metastases: A Case Report and Literature Review
    He, Xing
    Peng, Yaorong
    Zhou, Zhenyu
    Li, Wenbin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Analyses of intermediate-stage hepatocellular carcinoma patients receiving transarterial chemoembolization before designing clinical trials comparing transarterial chemoembolization and immune checkpoint inhibitor-based therapies
    Koroki, Keisuke
    Ogasawara, Sadahisa
    Ooka, Yoshihiko
    Kanzaki, Hiroaki
    Kanayama, Kengo
    Maruta, Susumu
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Saito, Tomoko
    Kondo, Takayuki
    Suzuki, Eiichiro
    Nakamoto, Shingo
    Tawada, Akinobu
    Chiba, Tetsuhiro
    Arai, Makoto
    Kanda, Tatsuo
    Maruyama, Hitoshi
    Kato, Jun
    Kuboki, Satoshi
    Ohtsuka, Masayuki
    Kato, Naoya
    JOURNAL OF HEPATOLOGY, 2020, 73 : S903 - S903
  • [36] Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Brandi, Giovanni
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2022, 7 (01): : 1 - 3
  • [37] Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma
    Garcia-Reyes, Kirema
    Gottlieb, Ricki A.
    Menon, Kartikeya M.
    Bishay, Vivian
    Patel, Rahul
    Patel, Rajesh
    Nowakowski, Scott
    Sung, Max W.
    Marron, Thomas U.
    Gansa, William H.
    Zhang, Jack
    Raja, Sahitya C.
    Shilo, Daniel
    Fischman, Aaron
    Lookstein, Robert
    Kim, Edward
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2024, 35 (05) : 722 - 730.e1
  • [38] Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies
    Li, Xiaoying
    Xiao, Chaoxin
    Li, Ruizhen
    Zhang, Pei
    Yang, Heqi
    Cao, Dan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [39] Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
    Mohr, Raphael
    Jost-Brinkmann, Fabian
    Ozdirik, Burcin
    Lambrecht, Joeri
    Hammerich, Linda
    Loosen, Sven H.
    Luedde, Tom
    Demir, Munevver
    Tacke, Frank
    Roderburg, Christoph
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [40] Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview
    Li, Jingjing
    Xu, Xuanfu
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2023, 16 : 1527 - 1540
12345